Editorial Comment to Efficacy of mirabegron, a β3 -adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies
- PMID: 34605071
- DOI: 10.1111/iju.14716
Editorial Comment to Efficacy of mirabegron, a β3 -adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies
Comment on
-
Efficacy of mirabegron, a β3 -adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies.Int J Urol. 2022 Jan;29(1):7-15. doi: 10.1111/iju.14700. Epub 2021 Oct 4. Int J Urol. 2022. PMID: 34605079 Free PMC article. Clinical Trial.
Similar articles
-
Efficacy of mirabegron, a β3 -adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies.Int J Urol. 2022 Jan;29(1):7-15. doi: 10.1111/iju.14700. Epub 2021 Oct 4. Int J Urol. 2022. PMID: 34605079 Free PMC article. Clinical Trial.
-
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).Eur Urol. 2020 Feb;77(2):211-220. doi: 10.1016/j.eururo.2019.10.002. Epub 2019 Nov 13. Eur Urol. 2020. PMID: 31733990 Clinical Trial.
-
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.Eur Urol. 2015 Jan;67(1):11-14. doi: 10.1016/j.eururo.2014.06.052. Epub 2014 Aug 2. Eur Urol. 2015. PMID: 25092537 Clinical Trial.
-
[The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].Ginekol Pol. 2014 Mar;85(3):214-9. doi: 10.17772/gp/1716. Ginekol Pol. 2014. PMID: 24783434 Review. Polish.
-
Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient.Clin Interv Aging. 2020 Apr 23;15:575-581. doi: 10.2147/CIA.S174402. eCollection 2020. Clin Interv Aging. 2020. PMID: 32368024 Free PMC article. Review.
References
-
- Takahashi S, Mishima Y, Kuroishi K, Ukai M. Efficacy of mirabegron, a β3-adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies. Int. J. Urol. 2022; 29: 7-15.
-
- Yamanishi T, Kaga K, Sakata K et al. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourol. Urodyn. 2020; 39: 804-12.
-
- Minagawa T, Gotoh M, Yokoyama O et al. Therapeutic effect of propiverine hydrochloride on mixed-type urinary incontinence in female; the Female Urgency and Stress Urinary Incontinence Study of Propiverine Hydrochloride (FRESH) trial. Int. J. Urol. 2018; 25: 486-91.
-
- Yamanishi T, Yasuda K, Tojo M, Hattori T, Sakakibara R, Shimazaki J. Effects of beta2-stimulants on contractility and fatigue of canine urethral sphincter. J. Urol. 1994; 151: 1066-9.
-
- Yamanishi T, Chapple CR, Yasuda K, Yoshida K, Chess-Williams R. The functional role of β-adrenoceptor subtypes in mediating relaxation of the pig urethral smooth muscle. J. Urol. 2003; 170: 2508-11.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical